Pieris Pharmaceuticals stock (US72016P1057): what delisting and liquidation mean for investors

Pieris Pharmaceuticals has been delisted and is in liquidation after strategic setbacks and failed deals. What this means for shareholders and how the biotech’s story evolved remains relevant for risk-aware investors following small-cap drug developers.

Pieris Pharmaceuticals has largely disappeared from major trading screens after the biotech was delisted and moved into liquidation, following a series of strategic setbacks and terminated partnerships that undermined its development pipeline, according to a corporate actions overview by Robinhood referencing Pieris as delisted pending liquidation as of 2024 (Robinhood corporate actions as of 2024).

The company had already signaled its winding-down path in 2023, when it announced cost-cutting, asset reviews and the exploration of strategic alternatives after losing key collaborations in respiratory and immuno-oncology, as described in its prior investor communications (Pieris investor information as of 2023). For investors, the case of Pieris illustrates how quickly fortunes can change in high-risk biotech when external funding and partner support evaporate.

As of: 16.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Pieris Pharmaceuticals, Inc.
• Sector/industry: Biotechnology / biopharmaceuticals
• Headquarters/country: Boston, United States
• Core markets: Respiratory and immuno-oncology drug development
• Key revenue drivers: Collaboration payments, milestone payments, potential future product royalties
• Home exchange/listing venue: Formerly Nasdaq (ticker: PIRS)
• Trading currency: U.S. dollar (USD)

Pieris Pharmaceuticals: core business model

Pieris Pharmaceuticals was a clinical-stage biotechnology company focused on developing protein-based therapeutics for respiratory diseases and cancer, building on its proprietary Anticalin technology platform that aimed to create small, engineered proteins targeting specific disease pathways, as outlined in earlier company presentations and filings (Pieris company overview as of 2023). Rather than marketing approved products, Pieris’ model relied on advancing candidates through clinical trials and monetizing them via licensing, co-development deals and potential future royalties.

The Anticalin approach sought to offer an alternative to traditional monoclonal antibodies by combining high target specificity with smaller molecular size and potentially improved tissue penetration, particularly relevant for inhaled respiratory therapies. Pieris positioned itself as a partner for larger pharmaceutical firms that could provide development funding and commercial muscle, while Pieris contributed discovery, early clinical expertise and access to its platform, according to management commentary in earlier investor materials (Pieris investor materials as of 2022).

Because the company did not generate significant recurring product revenue, it depended heavily on upfront payments, R&D reimbursements and potential milestones from collaboration agreements. This made Pieris highly sensitive to partner decisions, clinical data readouts and capital market conditions. When partnerships were terminated or programs did not progress as expected, Pieris’ ability to fund its pipeline and maintain a Nasdaq listing weakened, ultimately contributing to the delisting and liquidation process referenced in corporate actions trackers (Robinhood corporate actions as of 2024).

Main revenue and product drivers for Pieris Pharmaceuticals

During its active years on Nasdaq, Pieris’ potential value proposition centered on a handful of pipeline candidates and collaboration programs. In respiratory disease, one notable focus was an inhaled therapy targeting IL-4 and IL-13 pathways, initially developed with a large pharmaceutical partner to address severe asthma and related indications, according to previous Pieris pipeline disclosures (Pieris news releases as of 2022). In oncology, bispecific Anticalins aiming to engage immune cells against tumors were highlighted as long-term growth drivers, with Pieris seeking to leverage its platform to design molecules with flexible binding profiles.

In financial terms, collaboration payments and milestones formed the backbone of Pieris’ revenue profile, rather than product sales. Annual and quarterly reports showed that relatively modest collaboration revenue could produce notable year-on-year variability, since single upfront payments or milestones tied to clinical progress could significantly influence reported figures in a given period, as reflected in Pieris’ historical filings (Pieris Form 10-K as of 03/2023). This concentration risk meant that the termination of one major collaboration could materially impact the company’s outlook.

From an investor’s perspective, the key drivers for Pieris shares were therefore pipeline milestones, partner decisions and financing events. Positive phase 1 or phase 2 data, new or expanded deals with global pharma companies, and capital raises at acceptable terms were typically viewed as supportive, while clinical setbacks, terminated collaborations or indications of funding pressure weighed heavily on sentiment. The eventual liquidation scenario underscores how a dependency on external partners and capital can amplify downside risk for small biotechs when several negatives strike in close succession, as seen in Pieris’ later trajectory (Robinhood corporate actions as of 2024).

Why Pieris Pharmaceuticals matters for US investors

Even though Pieris Pharmaceuticals has been delisted and is in liquidation, its development arc remains instructive for US investors who follow emerging biotech names listed on Nasdaq or other US exchanges. Pieris’ journey from promising platform story to wind-down illustrates the binary nature of value creation in this segment, where a few pivotal clinical or strategic decisions can significantly alter equity outcomes, as evidenced in prior company updates and the subsequent corporate actions reports (Pieris investor information as of 2023).

For US-based portfolios, Pieris also highlights the need to understand counterparty risk in collaboration-heavy business models. When large pharmaceutical partners reprioritize their pipelines or budgets, smaller collaborators may face abrupt changes to funding and development timelines. In the case of Pieris, the combination of collaboration changes, funding challenges and market conditions ultimately led to delisting and liquidation, as reflected in the broker corporate actions tracker (Robinhood corporate actions as of 2024). This context can be relevant when US investors assess other early-stage biotech stocks with similar dependency profiles.

Conclusion

Pieris Pharmaceuticals moved from being a platform-focused clinical-stage biotech with high hopes in respiratory and cancer therapies to a company facing delisting and liquidation after strategic and financing setbacks, as documented in investor materials and corporate actions trackers (Pieris investor information as of 2023). The story underlines how dependence on a few key partnerships and the absence of commercialized products can leave smaller biotech firms vulnerable when conditions turn. For US investors, Pieris’ trajectory serves as a case study in the risks and potential rewards associated with early-stage drug developers, reinforcing the need for careful assessment of funding, pipeline concentration and partner stability before engaging with similar stocks.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.